title: Unfractionated heparin reduces the anti-platelet effects of abciximab but not eptifibatide during PCI.
abstract: In 29 patients undergoing percutaneous coronary intervention (PCI), we obtained blood samples at baseline, 10 minutes after standard weight-based abciximab (n=15) or double-bolus eptifibatide (n=14) and 5 minutes after unfractionated heparin (UFH; 70 U/kg bolus). The median percent inhibition was significantly higher in the eptifibatide group compared with the abciximab group both before (96.5% [94-100] vs. 85% [77-89.5] [adenosine diphosphate; ADP]; 89.5% [84-95] vs. 59% [37.5-76.5] [thrombin receptor agonist peptide; TRAP], p<0.001 for both) and after UFH (95% [93-100] vs. 79% [68.8-87.5] [ADP]; 82% [77-93] vs. 51% [34.5-71.3] [TRAP], p<0.001 for both). Addition of UFH significantly reduced platelet inhibition in the abciximab group (85% [77-89.5] vs. 79% [68.8-87.5] [ADP]; 59% [37.5-76.5] vs. 51% [34.5-71.3] [TRAP], p<0.05 for both) but not in the eptifibatide group (96.5% [94-100] vs. 95% [93-100] [ADP]; 89.5% [84-95] vs. 82% [77-93] [TRAP], p=ns for both). Eptifibatide achieved superior platelet inhibition before but especially after UFH compared with abciximab.
authors.affiliation: Wake Forest University School of Medicine, Winston-Salem, NC 27157-1045, USA.
authors.forename: Efthymios N
authors.initials: EN
authors.lastname: Deliargyris
authors.forename: Bharathi
authors.initials: B
authors.lastname: Upadhya
authors.forename: Laura G
authors.initials: LG
authors.lastname: Melton
authors.forename: Cheryl
authors.initials: C
authors.lastname: Thompson
authors.forename: Melrose
authors.initials: M
authors.lastname: Fisher
authors.forename: Don A
authors.initials: DA
authors.lastname: Gabriel
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Dehmer
authors.forename: David C
authors.initials: DC
authors.lastname: Sane
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D000077542:Eptifibatide; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010455:Peptides / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D006493:Heparin; D000077542:Eptifibatide; D000077284:Abciximab